🔴 LLY is trading 5.2% down today on profit-taking after a massive post-earnings rally

LLY is trading at $1,049.37 (-5.2%) as investors lock in gains following a +10.3% surge driven by blowout Q4 earnings and strong future guidance.

• The company reported Q4 revenue of $19.3B (up 43%) and an EPS beat of $7.54, while issuing robust 2026 revenue guidance of $80–83B.
• Today's pullback is exacerbated by broader market weakness, with the S&P 500 down 0.57% and the healthcare sector lagging behind the general market.
• Despite the decline, core fundamentals remain strong as high-demand GLP-1 drugs Mounjaro and Zepbound continue to drive significant growth momentum.